| Literature DB >> 31022998 |
Gehane M Hamed1, Wessam E Morsy1, Manal S Abd-El Hamid1, Arwa Abd El Moniem Hassan1, Fatma A Abu Zahra2.
Abstract
BACKGROUND AND OBJECTIVES: Bone marrow-derived mesenchymal stem cells (BM-MSCs) are adult multipotent non-haematopoietic stem cells that have regeneration potential. The current study aimed to detect the ability of BM-MSCs to improve kidney and cardiac functions in adult rats with established chronic kidney disease.Entities:
Keywords: Bone marrow-derived stem cells; Chronic kidney disease; Isolated perfused heart study; Nephrectomy
Year: 2019 PMID: 31022998 PMCID: PMC6657945 DOI: 10.15283/ijsc18114
Source DB: PubMed Journal: Int J Stem Cells ISSN: 2005-3606 Impact factor: 2.500
Fig. 1(A) Bone marrow-derived mesenchymal stem cells at culture days 1 and 8. (B) MSCs show negative expression of CD34 and positive expression of CD44 (f 400z×).
The body weight percentage change (BW %change), kidney tissue weight (mg), heart weights, and serum urea and creatinine (mg/dl) levels in the three studied groups: sham-operated control (Sham), untreated subtotally nephrectomized (untreated STNx) and treated subtotally nephrectomized (treated STNx) groups
| Sham ( | Untreated STNx ( | Treated STNx ( | |
|---|---|---|---|
| BW% change | 23.02±1.21 | 13.31±2.61 | 27.61±1.74 |
| Left kidney remnant weight (mg) | 787.14±34.35 | 737.52±35.69 | 1047.78±53.26 |
| LV (mg) | 518.81±11.69 | 569±16.71 | 588.27±18.17 |
| LV/BW (mg/gm) | 2.09±0.05 | 2.47±0.08 | 2.30±0.05 |
| WH/BW (mg/gm) | 3.03±0.09 | 3.63±0.18 | 3.37±0.08 |
| Creatinine (mg/dl) | 0.47±0.02 | 1.17±0.07 | 0.66±0.02 |
| Urea (mg/dl) | 33.54±1.31 | 67.15±3.47 | 42.85±1.72 |
The number of observations is shown in parentheses. All values are expressed as the mean±SEM.
Significant difference between the untreated subtotally nephrectomized (untreated STNx) group and sham-operated control group (Sham) as calculated by the LSD at p<0.05.
Significant difference between the treated subtotally nephrectomized group (treated STNx) group and the untreated subtotally nephrectom-ized (untreated STNx) group as calculated by the LSD at p<0.05.
Peak tension (PT) and peak tension per left ventricular weight (PT/LV), Time to peak tension (TPT), half relaxation time (HRT) and contraction time (CT) in the three studied groups: sham-operated control (Sham), untreated subtotally nephrectomized (untreated STNx) and treated subtotally nephrectomized (treated STNx) groups
| Sham ( | Untreated STNx ( | Treated STNx ( | |
|---|---|---|---|
| PT (gm) | 6.28±0.26 | 6.00±0.22 | 7.33±0.42 |
| Pre-ischaemia baseline | |||
| 5 min of reperfusion | 4.77±0.33 | 4.34±0.40 | 4.86±0.29 |
| 15 min of reperfusion | 4.69±0.39 | 3.84±0.37 | 4.97±0.30 |
| 30 min of reperfusion | 4.29±0.30 | 3.07±0.29 | 5.11±0.30 |
| PT/LV (gm/100 mg) | 1.23±0.30 | 1.17±0.27 | 1.19±0.35 |
| Pre-ischaemia baseline | |||
| 5 min of reperfusion | 0.91±0.28 | 0.87±0.37 | 0.79±0.24 |
| 15 min of reperfusion | 0.91±0.35 | 0.76±0.33 | 0.84±0.29 |
| 30 min of reperfusion | 0.82±0.27 | 0.60±0.25 | 0.83±0.24 |
| TPT (msec) | 113.67±8.27 | 120.33±7.93 | 89±2.14 |
| Pre-ischaemia baseline | |||
| 5 min of reperfusion | 133.67±11.07 | 137±11.75 | 91±3.39 |
| 15 min of reperfusion | 110.33±8.24 | 150.67±12.58 | 91.67±3.30 |
| 30 min of reperfusion | 114.33±9.17 | 165.67±11.61 | 93.33±3.44 |
| HRT (msec) | 80.67±7.05 | 67.33±5.16 | 75±2.84 |
| Pre-ischaemia baseline | |||
| 5 min of reperfusion | 99.33±10.75 | 86.67±6.70 | 86.67±3.80 |
| 15 min of reperfusion | 97.67±7.86 | 95±8.31 | 85±2.13 |
| 30 min of reperfusion | 94.33±8.90 | 103.33±6.82 | 83.67±3.67 |
| CT (msec) | 194.33±10.63 | 184.67±10.29 | 164±3.85 |
| Pre-ischaemia baseline | |||
| 5 min of reperfusion | 233±15.90 | 223±14.97 | 177.67±6.11 |
| 15 min of reperfusion | 208±12.42 | 243±15.60 | 176.67±3.92 |
| 30 min of reperfusion | 208.67±14.70 | 269±12.73 | 177±5.60 |
The number of observations is shown in parentheses. All values are expressed as the mean±SEM.
Significant difference between the untreated subtotally nephrectomized (untreated STNx) group and sham-operated control group (Sham) as calculated by the LSD at p<0.05.
Significant difference between the treated subtotally nephrectomized group (treated STNx) group and the untreated subtotally nephrectom-ized (untreated STNx) group as calculated by the LSD at p<0.05.
Significant difference from their initial values as calculated by Student’s t-test for paired data.
Fig. 2Initial, 4-week and 8-week (a) systolic blood pressure (SBP), (b) diastolic blood pressure and (c) mean arterial blood pressure values in the three studied groups. *: Significant difference compared to their initial values as calculated by Student’s t-test for paired data. a: Significant difference compared to the sham-operated control (Sham) group as calculated by the LSD at p<0.05. b: Significant difference compared to the untreated subtotally nephrectomized (untreated STNx) group as calculated by the LSD at p<0.05.
Fig. 4Histopathological changes in 1-Control group: (A) Renal tissues (B) Cardiac muscles. 2-Untreated nephrectomised group (A) Renal tissues showing hypertrophy of the glomerular tufts and congestion of renal blood vessels (B) Cardiac muscle showing intramuscular oedema that caused dispersion of the cardiomyocytes. 3-MSCs treated group (A) Renal tissues showing apparent normal renal parenchyma (B) Cardiac muscles showing regained normal morphology (H&E ×400).
Electrocardiographic changes in the three studied groups: sham-operated control (Sham), untreated subtotally nephrectomized (untreated STNx) and treated subtotally nephrectomized (treated STNx) groups
| Sham ( | Untreated STNx ( | Treated STNx ( | |
|---|---|---|---|
| Heart rate (bpm) | 235.67±5.46 | 207.43±12.77 | 232±4.36 |
| PR interval (msec) | 91.43±4.04 | 80±4.78 | 104.44±4.73 |
| QRS duration (msec) | 40±0 | 30.48±2.62 | 40±0 |
| QRS voltage ( | 695.24±41.68 | 466.67±47.97 | 750±72.87 |
| Q-To (msec) | 129.52±3.81 | 172±6.55 | 137.78±4.82 |
| Q-Tc (msec) | 258.57±6.10 | 323.50±7.69 | 273.33±9.53 |
The number of observations is shown in parentheses. All values are expressed as the mean±SEM.
Significant difference between the untreated subtotally nephrectomized (untreated STNx) group and sham-operated control group (Sham) as calculated by the LSD at p<0.05.
Significant difference between the treated subtotally nephrectomized group (treated STNx) group and the untreated subtotally nephrectom-ized (untreated STNx) group as calculated by the LSD at p<0.05.
Heart rate and Myocardial flow rate/100 mg of left ventricle (MFR/LV, ml/min/100 mg), in the three studied groups: sham-operated control (Sham), untreated subtotally nephrectomized (untreated STNx) and treated subtotally nephrectomized (treated STNx) groups
| Sham ( | Untreated STNx ( | Treated STNx ( | |
|---|---|---|---|
| HR (bpm) | 160±11.88 | 160.53±15.34 | 184.20±8.56 |
| Pre-ischaemia baseline | |||
| 5 min of reperfusion | 130.93±15.24 | 132.13±14.53 | 198.53±14.82 |
| 15 min of reperfusion | 134.07±9.57 | 133.87±15.14 | 179.80±13.48 |
| 30 min of reperfusion | 133.33±10.29 | 122.60±14.55 | 170.53±15.19 |
| MFR/LV (ml/min/100 mg) | |||
| Pre-ischaemia baseline | 1.20±0.16 | 1.10±0.09 | 1.20±0.08 |
| 5 min of reperfusion | 0.89±0.11 | 0.97±0.08 | 0.96±0.07 |
| 15 min of reperfusion | 0.78±0.11 | 0.87±0.09 | 0.76±0.05 |
| 30 min of reperfusion | 0.68±0.10 | 0.66±0.06 | 0.66±0.06 |
Significant difference from their initial values as calculated by Student’s t-test for paired data.
The number of observations is shown in parentheses. All values are expressed as the mean±SEM.
Significant difference between the untreated subtotally nephrectomized (untreated STNx) group and sham-operated control group (Sham) as calculated by the LSD at p<0.05.
Significant difference between the treated subtotally nephrectomized group (treated STNx) group and the untreated subtotally nephrectom-ized (untreated STNx) group as calculated by the LSD at p<0.05.
Fig. 3Results of the PCR assay for the male Y chromosome (sry) gene following 2% agarose gel electrophoresis and staining with ethidium bromide. M: DNA 100-bp marker, PC: positive PCR control (male rat genomic DNA), NC: negative PCR control (female rat genomic DNA). Lane 1~4: MSC-treated group, which was injected with mesenchymal stem cells (MSCs). Lane 5~8: Control and untreated groups that were not injected with male MSCs.